D-1093-2023 Class II Terminated

Recalled by Parker Laboratories, Inc. — Fairfield, NJ

FDA drug recall D-1093-2023 was initiated by Parker Laboratories, Inc. on Aug 2, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jun 3, 2024). Affected quantity: 50.

Recall details

Product Type
Drugs
Report Date
Aug 30, 2023
Initiation Date
Aug 2, 2023
Termination Date
Jun 3, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
50

Product description

Helix CBD Clinical Cream (Menthol 7.4%), packaged in a)3 gm pouches (NDC30775-054-01), b)2 fl. oz. tubes (NDC 30775-054-02), and c) 4 fl. oz. tubes (NDC 30775-054-04), Parker Laboratories, Inc. 286 Eldridge Road, Fairfield, NJ 07004

Reason for recall

CGMP Deviations

Distribution pattern

Nationwide within the United States, Singapore, Korea and Hong Kong

Code information

Lot #: a) J1121011, Exp. Date 12/21/2023, b) A0921009, Exp. Date 8/18/2023, c) A0921008, Exp. Date 8/18/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1093-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1093-2023. Report a data issue: hello@regdatalab.com.